These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28123287)

  • 1. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis.
    Spooner K; Hong T; Wijeyakumar W; Chang AA
    Clin Ophthalmol; 2017; 11():161-177. PubMed ID: 28123287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
    Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
    Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Barthelmes D; Nguyen V; Daien V; Campain A; Walton R; Guymer R; Morlet N; Hunyor AP; Essex RW; Arnold JJ; Gillies MC;
    Retina; 2018 Jan; 38(1):20-28. PubMed ID: 28145976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.
    Mantel I; Gillies MC; Souied EH
    Surv Ophthalmol; 2018; 63(5):638-645. PubMed ID: 29476754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
    Mehta H; Tufail A; Daien V; Lee AY; Nguyen V; Ozturk M; Barthelmes D; Gillies MC
    Prog Retin Eye Res; 2018 Jul; 65():127-146. PubMed ID: 29305324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies.
    Zhang Y; Chioreso C; Schweizer ML; Abràmoff MD
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5616-5627. PubMed ID: 29094167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
    Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
    JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes.
    Introini U; Casalino G
    Dev Ophthalmol; 2017; 60():71-77. PubMed ID: 28427067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy.
    Mira F; Paulo M; Henriques F; Figueira J
    J Ophthalmol; 2017; 2017():5632634. PubMed ID: 28348885
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.
    Kikushima W; Sakurada Y; Yoneyama S; Sugiyama A; Tanabe N; Kume A; Mabuchi F; Iijima H
    Sci Rep; 2017 Mar; 7():44020. PubMed ID: 28266609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration.
    Yamamoto A; Okada AA; Nakayama M; Yoshida Y; Kobayashi H
    Ophthalmologica; 2017; 237(3):139-144. PubMed ID: 28259869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents.
    Ruão M; Andreu-Fenoll M; Dolz-Marco R; Gallego-Pinazo R
    Clin Ophthalmol; 2017; 11():299-302. PubMed ID: 28203056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.
    Almuhtaseb H; Kanavati S; Rufai SR; Lotery AJ
    Eye (Lond); 2017 Jun; 31(6):878-883. PubMed ID: 28186507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.
    Jacob J; Brié H; Leys A; Levecq L; Mergaerts F; Denhaerynck K; Vancayzeele S; Van Craeyveld E; Abraham I; MacDonald K
    Int J Ophthalmol; 2017; 10(1):81-90. PubMed ID: 28149782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis.
    Guo MY; Etminan M; Cheng JZ; Zafari Z; Maberley DAL
    Pharmacotherapy; 2018 Feb; 38(2):197-204. PubMed ID: 29286545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
    Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
    Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.